Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ALT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | State Street Corporation | 8.36M | 4.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Tang Capital Partners International, LP | 666,022 | 0.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Tang Capital Partners, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Kevin Tang | 666,022 | 0.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Tang Capital Management, LLC | 666,022 | 0.3% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | State Street Corporation | 7.15M | 5.5% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | RA Capital Healthcare Fund, L.P. | 13.00M | 6.5% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Rajeev Shah | 13.00M | 6.5% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Peter Kolchinsky | 13.00M | 6.5% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | RA Capital Management, L.P. | 13.00M | 6.5% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Chen Yu | 20.00M | 9.8% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | TCG Crossover Fund III, L.P. | 10.00M | 5.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | TCG Crossover GP III, LLC | 10.00M | 5.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | TCG Crossover Fund II, L.P. | 10.00M | 5.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | TCG Crossover GP II, LLC | 10.00M | 5.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Rose Sharon Shabet | 13.40M | 6.7% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Halvorsen Ole Andreas | 13.40M | 6.7% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities Vintage IV (Aggregator) LP | 4.02M | 2.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities Vintage IV Portfolio GP LLC | 4.02M | 2.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities Vintage IV GP LLC | 4.02M | 2.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities Illiquid Investments Sub-Master LP | 9.38M | 4.7% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities Portfolio GP LLC | 9.38M | 4.7% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities GP LLC | 9.38M | 4.7% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Opportunities Parent GP LLC | 13.40M | 6.7% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Viking Global Investors LP | 13.40M | 6.7% | SCHEDULE 13G ↗ |
| Apr 30, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Deep Track Special Opportunities Fund, LP. | 2.59M | 1.3% | SCHEDULE 13G ↗ |
| Apr 30, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | David Kroin | 19.42M | 10.0% | SCHEDULE 13G ↗ |
| Apr 30, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 16.83M | 8.7% | SCHEDULE 13G ↗ |
| Apr 30, 2026 | SCHEDULE 13G | ALT Altimmune, Inc. | Deep Track Capital, LP | 19.42M | 10.0% | SCHEDULE 13G ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | The Vanguard Group | 9.49M | 9.1% | SCHEDULE 13G/A ↗ |
| Jul 16, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | BlackRock, Inc. | 6.13M | 7.6% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Investment Services Limited | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Asset Management Limited | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | TC Financing Ltd | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Asset Management Holdings Limited | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | TAM UK Holdings Limited | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Holdings Limited | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | TAM UK International Holdings Limited | 1.32M | 1.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Ameriprise Financial, Inc. | 1.44M | 1.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Investment Services Limited | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Asset Management Limited | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | TC Financing Ltd | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Asset Management Holdings Limited | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | TAM UK Holdings Limited | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Threadneedle Holdings Limited | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | TAM UK International Holdings Limited | 5.10M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ALT Altimmune, Inc. | Ameriprise Financial, Inc. | 5.25M | 7.4% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances